Related Experiment Video
Updated: Jul 5, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
New prognostic markers in chronic lymphocytic leukemia
Carol Moreno1, Emili Montserrat
1Institute of Hematology and Oncology, Department of Hematology, Hospital Clínic, IDIBAPS, University of Barcelona. camoreno@clinic.ub.es
Blood Reviews
|May 2, 2008
Summary
Prognosis for chronic lymphocytic leukemia (CLL) patients varies greatly. While new biologic markers show promise, clinical parameters remain key for predicting outcomes and guiding therapy decisions.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Prognosis in chronic lymphocytic leukemia (CLL) is highly variable.
- Traditionally, clinical parameters guide CLL prognostication.
- Emerging biologic markers offer potential prognostic insights.
Purpose of the Study:
- To review current prognostic factors in CLL.
- To discuss the role of novel biologic markers in predicting prognosis and therapy response.
- To highlight areas requiring further research and standardization.
Main Methods:
- Review of existing clinical and biologic prognostic parameters in CLL.
- Discussion of the clinical utility and standardization needs for markers like cytogenetics, IgVH mutations, CD38, and ZAP-70.
- Examination of specific genetic abnormalities (17p-, 11q-) and their prognostic significance.
Main Results:
- Clinical parameters and stages are currently the most reliable for CLL prognostication.
- Biologic markers (cytogenetics, IgVH, CD38, ZAP-70) require standardization and validation in prospective trials.
- 17p- deletions (p53 abnormalities) and 11q deletions (ATM defects) are significant markers for therapy response prediction.
Conclusions:
- Clinical parameters remain essential for CLL prognosis and management.
- Standardization and validation of novel biologic markers are crucial before widespread clinical adoption.
- Eradication of disease through therapy correlates with improved patient survival, emphasizing the importance of response prediction.
